AU2022226407A1 - New virus particles for therapeutic purposes - Google Patents
New virus particles for therapeutic purposes Download PDFInfo
- Publication number
- AU2022226407A1 AU2022226407A1 AU2022226407A AU2022226407A AU2022226407A1 AU 2022226407 A1 AU2022226407 A1 AU 2022226407A1 AU 2022226407 A AU2022226407 A AU 2022226407A AU 2022226407 A AU2022226407 A AU 2022226407A AU 2022226407 A1 AU2022226407 A1 AU 2022226407A1
- Authority
- AU
- Australia
- Prior art keywords
- segment
- lcmv
- particle
- seq
- vims
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159746 | 2021-02-26 | ||
| EP21159746.3 | 2021-02-26 | ||
| PCT/EP2022/054766 WO2022180203A1 (en) | 2021-02-26 | 2022-02-25 | New virus particles for therapeutic purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022226407A1 true AU2022226407A1 (en) | 2023-09-28 |
| AU2022226407A9 AU2022226407A9 (en) | 2024-01-25 |
Family
ID=74844711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022226407A Pending AU2022226407A1 (en) | 2021-02-26 | 2022-02-25 | New virus particles for therapeutic purposes |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4297763A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508823A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230153411A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117241812A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022226407A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208055A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023002508A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305349A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009650A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022180203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326615A (en) | 2023-08-31 | 2026-04-01 | Abalos Therapeutics Gmbh | Virus particles with improved entry into tumor cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3373959B1 (en) * | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
-
2022
- 2022-02-25 WO PCT/EP2022/054766 patent/WO2022180203A1/en not_active Ceased
- 2022-02-25 KR KR1020237032657A patent/KR20230153411A/ko active Pending
- 2022-02-25 CN CN202280030958.8A patent/CN117241812A/zh active Pending
- 2022-02-25 JP JP2023551984A patent/JP2024508823A/ja active Pending
- 2022-02-25 CA CA3208055A patent/CA3208055A1/en active Pending
- 2022-02-25 EP EP22711182.0A patent/EP4297763A1/en active Pending
- 2022-02-25 IL IL305349A patent/IL305349A/en unknown
- 2022-02-25 AU AU2022226407A patent/AU2022226407A1/en active Pending
- 2022-02-25 MX MX2023009650A patent/MX2023009650A/es unknown
-
2023
- 2023-08-24 CL CL2023002508A patent/CL2023002508A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL305349A (en) | 2023-10-01 |
| EP4297763A1 (en) | 2024-01-03 |
| CA3208055A1 (en) | 2022-09-01 |
| WO2022180203A1 (en) | 2022-09-01 |
| AU2022226407A9 (en) | 2024-01-25 |
| JP2024508823A (ja) | 2024-02-28 |
| US20220273741A1 (en) | 2022-09-01 |
| CL2023002508A1 (es) | 2024-01-26 |
| KR20230153411A (ko) | 2023-11-06 |
| CN117241812A (zh) | 2023-12-15 |
| MX2023009650A (es) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102838785B1 (ko) | 암호화 리보핵산의 기관 보호적 발현 및 조절을 위한 조성물 및 방법 | |
| JP5797638B2 (ja) | ニューロンの発生、再生および保護 | |
| CN108307642B (zh) | 改造的白介素12及其在制备治疗肿瘤药物中的用途 | |
| US20170368117A1 (en) | Multitargeting onocolytic adenovirus, methods of use, and methods of making | |
| US10604741B2 (en) | Compositions and methods for enhancing virus replication | |
| US20240424040A1 (en) | Oncolytic virus and use thereof | |
| JP2021519747A (ja) | 腫瘍を治療するための仮性狂犬病ウイルス | |
| AU2022226407A9 (en) | New virus particles for therapeutic purposes | |
| CN107223055A (zh) | 具有增强的促凋亡特性的基因修饰的传染性麻疹病毒(mv-deltac病毒)在癌症治疗中的用途 | |
| WO2019183802A1 (zh) | 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用 | |
| JP6108425B2 (ja) | 癌治療のための組換え麻疹ウイルス | |
| US11384338B2 (en) | Oncolytic T7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating melanoma | |
| Liu et al. | Evaluation of the impact of arginine–chitosan/DNA nanoparticles on human naive CD4+ T cells | |
| JP7857683B2 (ja) | 腫瘍溶解性ウイルス及びその使用 | |
| JP2022541030A (ja) | hnRNPA2B1の抗感染作用及びその応用 | |
| AU2023234944A1 (en) | Novel usage of oncolytic gene-modified measles virus | |
| WO2025119999A1 (en) | Extracellular vesicle based vaccine platform | |
| JP2023523652A (ja) | ウイルス感染に関連する疾患若しくは症候群の治療及び/又は予防 | |
| WO2025046106A1 (en) | Virus particles with improved entry into tumor cells | |
| Hanauer | Increasing oncoselectivity of virotherapy: Receptor targeted viruses against CD30-positive malignancies | |
| Brain | JVI Accepts, published online ahead of print on 7 November 2012 | |
| Thiel et al. | Type I IFN-Mediated Protection of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |